Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model.

This study investigates the long-term angiogenic effects of ANG-1 and VEGF in a swine chronic myocardial ischemia model. Four-weeks after gradual occlusion of the left circumflex coronary artery by ameroid constrictor, animals were injected with recombinant adenoviral vectors carrying either human ANG-1 (n=9), human VEGF(165) (n=10) or empty vector (n=7) into the left ventricle free wall supplied by the constricted artery. Left ventricular perfusion in animals that received AdANG-1 (3.25+/-0.16 ml/min/g, p<0.05) recovered robustly 4 weeks after gene transfer while ischemia persisted in the AdVEGF (1.09+/-0.13 ml/min/g) and empty vector (1.20+/-0.03 ml/min/g) groups. Microvascular densities in the left ventricles of animals that received AdANG-1 (19.61+/-1.76/0.572 mm(2) myocardial tissue, p<0.05) and AdVEGF (18.17+/-1.43/0.572 mm(2) myocardial tissue, p<0.05) were significantly higher than animals that received empty vector (13.53+/-0.92/0.572 mm(2) myocardial tissue) 12 weeks after gene transfer. ANG-1, but not VEGF, contributed to enhanced regional perfusion by increasing arteriolar density (1.9+/-0.4/0.572 mm(2) myocardial tissue vs. 0.7+/-0.2/0.572 mm(2) myocardial tissue, p<0.05) of large-sized (50-100 microm) arterioles. These data demonstrate that gene transfer of ANG-1 and VEGF enhances angiogenesis, but ANG-1 promotes sustained improvement of ventricular perfusion that expedites recovery of ischemic myocardium via arteriogenesis.

[1]  W. Schaper,et al.  Quantification of Collateral Resistance in Acute and Chronic Experimental Coronary Occlusion in the Dog , 1976, Circulation research.

[2]  Brian H Annex,et al.  Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. , 2003, Journal of applied physiology.

[3]  J. Isner,et al.  Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. , 1999, The Annals of thoracic surgery.

[4]  J. Isner,et al.  Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. , 1999, Human gene therapy.

[5]  B. Keyt,et al.  VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. , 1996, The Journal of surgical research.

[6]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[7]  G. Koh,et al.  Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. , 2001, Gastroenterology.

[8]  S. Rafii,et al.  Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.

[9]  L. Ye,et al.  High efficiency transduction of human VEGF165 into human skeletal myoblasts: in vitro studies , 2003, Experimental & Molecular Medicine.

[10]  J. Chae,et al.  Coadministration of Angiopoietin-1 and Vascular Endothelial Growth Factor Enhances Collateral Vascularization , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[11]  G. Koh,et al.  Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. , 2000, Circulation research.

[12]  L. Kedes,et al.  Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation. , 2000, Journal of the American College of Cardiology.

[13]  L. Ye,et al.  Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor , 2004, Journal of Molecular Medicine.

[14]  D. Schiffer,et al.  Expression of Angiopoietin-1 in Human Glioblastomas Regulates Tumor-Induced Angiogenesis: In Vivo and In Vitro Studies , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Capogrossi,et al.  Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. , 2003, Human gene therapy.

[16]  J. Longhurst,et al.  Development of coronary collateral circulation in left circumflex Ameroid-occluded swine myocardium. , 1987, The American journal of physiology.

[17]  W. Pearce,et al.  Up-regulation of vascular endothelial growth factor mRNA and angiogenesis after transmyocardial laser revascularization. , 1999, The Annals of thoracic surgery.

[18]  J. Lowe,et al.  Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study. , 2004, The Journal of thoracic and cardiovascular surgery.

[19]  R. Coleman,et al.  Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. , 2004, Annals of Thoracic Surgery.

[20]  J. Isner,et al.  Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. , 2003, Life sciences.

[21]  K. Sugimachi,et al.  Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 but not of Fibroblast Growth Factor-2 , 2002, Circulation research.

[22]  B. V. von Specht,et al.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. , 1998, Circulation.

[23]  W. Schaper,et al.  Time course of mitosis and collateral growth following coronary microembolization in the porcine heart , 1997, Cell and Tissue Research.

[24]  W. Schaper,et al.  Generation and localisation of monoclonal antibodies against fibroblast growth factors in ischaemic collateralised porcine myocardium. , 1993, Cardiovascular research.

[25]  E. Unger,et al.  Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. , 1999, Cardiovascular research.

[26]  T. Skalak,et al.  Spatial and temporal control of angiogenesis and arterialization using focal applications of VEGF164 and Ang-1. , 2004, American journal of physiology. Heart and circulatory physiology.

[27]  S. Epstein,et al.  Effects of gene delivery on collateral development in chronic hypoperfusion: diverse effects of angiopoietin-1 versus vascular endothelial growth factor. , 2004, Journal of the American College of Cardiology.

[28]  C. Little,et al.  Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Ye,et al.  In vitro functional assessment of human skeletal myoblasts after transduction with adenoviral bicistronic vector carrying human VEGF165 and angiopoietin-1. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  M. Post,et al.  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. , 1999, Circulation.

[31]  L. Varticovski,et al.  Opposing effect of angiopoietin‐1 on VEGF‐mediated disruption of endothelial cell–cell interactions requires activation of PKCβ , 2004, Journal of cellular physiology.

[32]  M. Eskandarpour,et al.  Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. , 2003, Biochemical and biophysical research communications.

[33]  J. Kim,et al.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.

[34]  Armin Helisch,et al.  Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. , 2002, Journal of molecular and cellular cardiology.

[35]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[36]  M. Teh,et al.  Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. , 2002, Experimental cell research.

[37]  R. Crystal,et al.  Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. , 1998, The Journal of thoracic and cardiovascular surgery.

[38]  J. Longhurst,et al.  Effect of long-term exercise on regional myocardial function and coronary collateral development after gradual coronary artery occlusion in pigs. , 1990, Circulation.

[39]  N. Copeland,et al.  Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  T. Takato,et al.  Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor. , 2004, Cardiovascular research.

[41]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[42]  D. Berman,et al.  The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003, Circulation.

[43]  R. Crystal,et al.  Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. , 1999, Human gene therapy.

[44]  G. Lip,et al.  Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. , 2004, Journal of the American College of Cardiology.

[45]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[46]  M. Siemionow,et al.  Enhancement of Muscle Flap Hemodynamics by Angiopoietin-1 , 2002, Annals of plastic surgery.

[47]  H. Hamada,et al.  Pre‐administration of angiopoietin‐1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model , 2003, The journal of gene medicine.

[48]  J. Pearlman,et al.  Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. , 2000, Journal of the American College of Cardiology.

[49]  J. Gamble,et al.  Angiopoietin-1 Is an Antipermeability and Anti-Inflammatory Agent In Vitro and Targets Cell Junctions , 2000, Circulation research.

[50]  T. Henry,et al.  Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.

[51]  Sachie Hirai,et al.  Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  D. Warltier,et al.  Expression of VEGF and angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. , 2003, American journal of physiology. Heart and circulatory physiology.

[53]  W. Sessa,et al.  Antiangiogenic therapy: creating a unique "window" of opportunity. , 2004, Cancer cell.